XFOR (X4 Pharmaceuticals) 3-Month Share Buyback Ratio: -3.75% (As of Mar. 2026 )


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.41
! 5 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals 3-Month Share Buyback Ratio?

X4 Pharmaceuticals XFOR +11.65% 24 3-Month Share Buyback Ratio is -3.75 as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. X4 Pharmaceuticals's current 3-Month Share Buyback Ratio was -3.75%.

X4 Pharmaceuticals  (NAS:XFOR) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

X4 Pharmaceuticals 3-Month Share Buyback Ratio Related Terms

XFOR vs CMPX, LRMR, PROK: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's 3-Month Share Buyback Ratio falls into.


XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals 3-Month Share Buyback Ratio Calculation

X4 Pharmaceuticals's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(90.907 - 94.320) / 90.907
=-3.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -3.75 mean?
X4 Pharmaceuticals (XFOR) has a 3-Month Share Buyback Ratio of -3.75 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' 3-Month Share Buyback Ratio too high?
X4 Pharmaceuticals' current 3-Month Share Buyback Ratio is -3.75. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' 3-Month Share Buyback Ratio compare to CMPX and LRMR?
X4 Pharmaceuticals' 3-Month Share Buyback Ratio of -3.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current 3-Month Share Buyback Ratio is -3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current 3-Month Share Buyback Ratio of -3.75. The current 3-Month Share Buyback Ratio is -3.75. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current 3-Month Share Buyback Ratio is -3.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price